Logo

Qiagen: May 10, 2007

May 10, 2007
Premium
Qiagen recently introduced the FlexiTube siRNA, a line of siRNAs against customer-specified targets available in one nanomolar amounts.
 
According to the company, FlexiTube allows customers to order a small number of siRNAs in cost-effective quantities. The siRNAs come lyophilized in tubes.
 
Qiagen also introduced this week the MiScript line of microRNA assay technologies.
The line incorporates a technology that allows researchers to identify multiple miRNAs from a single cDNA reaction in a given biological sample, the company said.

Filed under

Gene Editing, Gene Silencing, & CRISPR
RNAi
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.